Recently, we demonstrated in GEP-NEC in vitro as well as in vivo that inhibitor of apoptosis protein (IAP) family member survivin/BIRC5 could be such a druggable target (Dizdar et al. 2017). The gene discussed is BIRC5; the disease is neuroendocrine carcinoma.